Tag:

Profectus Biosciences

Latest Headlines

Latest Headlines

Baltimore's Profectus BioSciences starts PhI trial of Ebola vaccine

January 19, 2016 | By
Back in October 2014, Profectus BioSciences scored $9.5 million in Department of Defense funding to manufacture its trivalent vaccine to protect against Ebola and Marburg viruses. Now, the Baltimore-based biotech is taking its Ebola candidate to Phase I trials.

Ebola roundup: J&J; invests $200M in R&D;, Glaxo says vaccine will come too late

October 23, 2014 | By
As the Ebola outbreak continues with deadly momentum, drugmakers are working at lightning speed to develop a vaccine.

Profectus immunizes first patient in Ph1 HIV vax trial

May 26, 2011 | By
Baltimore-based Profectus Biosciences has inoculated its first patient in a Phase I trial of its multi-antigen DNA HIV vaccine. The study will monitor 60 HIV patients who are on stable
Related Tags
Press Releases
  • Opening Arguments Today in Largest US Pharma Theft Civil Suit
  • Award of Funding for Next Stage of US Department of Defense Programme to Develop Genedrive® Biohazard Identification Tests
  • Men in England to finally have routine access to UK-discovered prostate cancer medicine Zytiga (abiraterone acetate) before chemotherapy
  • Switching to Remsima®▼ (infliximab) from originator has no negative effect on safety or efficacy in 10 real-world studies
  • The Myriad myRisk Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Cancer
  • More Press Releases
Sponsored Links